Daré Bioscience, Inc.
DARE
$1.92
$0.073.78%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -85.10% | 44,408.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -85.10% | 44,408.70% | |||
| Cost of Revenue | 119.60% | -491.89% | |||
| Gross Profit | -113.33% | 579.94% | |||
| SG&A Expenses | 42.58% | -36.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.31% | -32.10% | |||
| Operating Income | -103.83% | 59.93% | |||
| Income Before Tax | -108.08% | 59.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -108.08% | 59.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -108.08% | 59.53% | |||
| EBIT | -103.83% | 59.93% | |||
| EBITDA | -160.89% | 70.63% | |||
| EPS Basic | -104.76% | 63.87% | |||
| Normalized Basic EPS | -104.60% | 63.86% | |||
| EPS Diluted | -2.23% | 27.82% | |||
| Normalized Diluted EPS | -104.60% | 63.86% | |||
| Average Basic Shares Outstanding | 1.66% | 12.00% | |||
| Average Diluted Shares Outstanding | 1.66% | 12.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||